BACKGROUND: Bone is among the most common sites of metastasis in patients with advanced cancer, and the development of bone metastases places patients at increased risk for skeletal complications. METHODS: This retrospective claims analysis included only patients with a diagnosis of bone metastasis who had a single type of solid tumor of the breast (women), prostate, or lung and experienced >or=1 skeletal complication between January 2002 and October 2005. RESULTS: The mean follow-up (+/-standard deviation) for zoledronic acid (ZA)-treated patients versus untreated patients was 12.2 +/- 9.05 months versus 8.7 +/- 9.28 months, respectively (P < .001). The monthly rate of skeletal complications in ZA-treated patients versus untreated patients was 0.29 +/- 0.3 per month versus 0.43 +/- 0.4 per month, respectively (P < .001). Persistent ZA use was associated with longer follow-up duration (P < .05) and a greater probability of continuing follow-up. Greater persistency was associated with lower monthly rates of skeletal complications (P < .05). The length of follow-up for ZA use according to the recommended dosing schedule was 17.11 months compared with 9.93 months for nonrecommended schedules and 8.68 months for no treatment (analysis of variance; P < .001). The rate of skeletal complications with ZA use on the recommended schedule was 0.16 events per month versus 0.31 events per month for nonrecommended schedules and 0.43 events per month for no treatment. In the subgroup analysis, the mean time to first complication was 185 +/- 210 days in the ZA-treated group versus 98 +/- 161 days in the untreated group (P < .0001). The mean time from the first complication to the second complication was 111 +/- 124 days in the ZA-treated group versus 86 +/- 114 days in the untreated group (P < .05). CONCLUSIONS: Real-world evidence indicated that ZA reduced the skeletal morbidity rate and delayed the time to skeletal complications. (c) 2008 American Cancer Society.
BACKGROUND: Bone is among the most common sites of metastasis in patients with advanced cancer, and the development of bone metastases places patients at increased risk for skeletal complications. METHODS: This retrospective claims analysis included only patients with a diagnosis of bone metastasis who had a single type of solid tumor of the breast (women), prostate, or lung and experienced >or=1 skeletal complication between January 2002 and October 2005. RESULTS: The mean follow-up (+/-standard deviation) for zoledronic acid (ZA)-treated patients versus untreated patients was 12.2 +/- 9.05 months versus 8.7 +/- 9.28 months, respectively (P < .001). The monthly rate of skeletal complications in ZA-treated patients versus untreated patients was 0.29 +/- 0.3 per month versus 0.43 +/- 0.4 per month, respectively (P < .001). Persistent ZA use was associated with longer follow-up duration (P < .05) and a greater probability of continuing follow-up. Greater persistency was associated with lower monthly rates of skeletal complications (P < .05). The length of follow-up for ZA use according to the recommended dosing schedule was 17.11 months compared with 9.93 months for nonrecommended schedules and 8.68 months for no treatment (analysis of variance; P < .001). The rate of skeletal complications with ZA use on the recommended schedule was 0.16 events per month versus 0.31 events per month for nonrecommended schedules and 0.43 events per month for no treatment. In the subgroup analysis, the mean time to first complication was 185 +/- 210 days in the ZA-treated group versus 98 +/- 161 days in the untreated group (P < .0001). The mean time from the first complication to the second complication was 111 +/- 124 days in the ZA-treated group versus 86 +/- 114 days in the untreated group (P < .05). CONCLUSIONS: Real-world evidence indicated that ZA reduced the skeletal morbidity rate and delayed the time to skeletal complications. (c) 2008 American Cancer Society.
Authors: Thomas Delea; Corey Langer; James McKiernan; Martin Liss; John Edelsberg; Jane Brandman; Jennifer Sung; Monika Raut; Gerry Oster Journal: Oncology Date: 2004 Impact factor: 2.935
Authors: Eva Corey; Lisha G Brown; Janna E Quinn; Martin Poot; Martine P Roudier; Celestia S Higano; Robert L Vessella Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Bruce E Hillner; James N Ingle; Rowan T Chlebowski; Julie Gralow; Gary C Yee; Nora A Janjan; Jane A Cauley; Brent A Blumenstein; Kathy S Albain; Allan Lipton; Susan Brown Journal: J Clin Oncol Date: 2003-09-08 Impact factor: 44.544
Authors: Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman Journal: Bone Date: 2010-11-10 Impact factor: 4.398
Authors: Heidi V Russell; Susan G Groshen; Tasnim Ara; Yves A DeClerck; Randy Hawkins; Hollie A Jackson; Heike E Daldrup-Link; Araz Marachelian; Andrej Skerjanec; Julie R Park; Howard Katzenstein; Katherine K Matthay; Susan M Blaney; Judith G Villablanca Journal: Pediatr Blood Cancer Date: 2010-11-12 Impact factor: 3.167
Authors: Fred Saad; Neil E Fleshner; Alan So; Jacques Le Lorier; Louise Perrault; Melanie Poulin-Costello; Raina Rogoza; Ewan J D Robson Journal: Can Urol Assoc J Date: 2018-06-19 Impact factor: 1.862
Authors: Gerry Oster; Lois Lamerato; Andrew G Glass; Kathryn E Richert-Boe; Andrea Lopez; Karen Chung; Akshara Richhariya; Tracy Dodge; Greg G Wolff; Arun Balakumaran; John Edelsberg Journal: Support Care Cancer Date: 2014-01-04 Impact factor: 3.603
Authors: Gerry Oster; Lois Lamerato; Andrew G Glass; Kathryn E Richert-Boe; Andrea Lopez; Karen Chung; Akshara Richhariya; Tracy Dodge; Greg G Wolff; Arun Balakumaran; John Edelsberg Journal: Support Care Cancer Date: 2013-07-25 Impact factor: 3.603
Authors: T Van den Wyngaert; M Delforge; C Doyen; L Duck; K Wouters; I Delabaye; C Wouters; H Wildiers Journal: Support Care Cancer Date: 2013-08-18 Impact factor: 3.603
Authors: Rohini K Hernandez; Jane Quigley; Melissa Pirolli; David Quach; Kristina S Chen; Jorge Arellano; Alexander Liede Journal: Support Care Cancer Date: 2014-05-02 Impact factor: 3.603
Authors: Robert E Goldsby; Timothy M Fan; Doojduen Villaluna; Lars M Wagner; Michael S Isakoff; James Meyer; R Lor Randall; Sharon Lee; Grace Kim; Mark Bernstein; Richard Gorlick; Mark Krailo; Neyssa Marina Journal: Eur J Cancer Date: 2013-05-07 Impact factor: 9.162